Compare Stocks → The Next Nvidia? (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CRDFNASDAQ:INMBNYSE:IVCNASDAQ:LVTX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDFCardiff Oncology$4.36+0.2%$4.12$0.94▼$6.42$194.35M1.931.03 million shs461,200 shsINMBINmune Bio$10.63+27.0%$11.57$6.50▼$14.74$152.36M1.99107,454 shs686,517 shsIVCInvacare$0.50$0.33▼$2.53$20.01M0.38240,305 shs33,301 shsLVTXLAVA Therapeutics$2.85+5.2%$2.76$1.13▼$6.47N/A0.64271,877 shs87,665 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDFCardiff Oncology+0.23%-17.42%-25.47%+184.97%+194.59%INMBINmune Bio+26.94%+10.91%-12.91%-4.02%+44.56%IVCInvacare0.00%0.00%0.00%0.00%0.00%LVTXLAVA Therapeutics+5.17%-2.73%-21.92%+86.27%+74.85%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRDFCardiff Oncology0.5332 of 5 stars3.52.00.00.00.00.00.0INMBINmune Bio0.826 of 5 stars3.50.00.00.01.91.70.0IVCInvacareN/AN/AN/AN/AN/AN/AN/AN/ALVTXLAVA Therapeutics1.5504 of 5 stars3.55.00.00.00.00.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDFCardiff Oncology3.00Buy$10.50140.83% UpsideINMBINmune Bio3.00Buy$16.0050.59% UpsideIVCInvacareN/AN/AN/AN/ALVTXLAVA Therapeutics3.00Buy$6.00110.53% UpsideCurrent Analyst RatingsLatest LVTX, IVC, TSTL, CRDF, and INMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2024LVTXLAVA TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/6/2024CRDFCardiff OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $14.003/1/2024CRDFCardiff OncologyPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$5.00 ➝ $7.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDFCardiff Oncology$490K397.56N/AN/A$1.56 per share2.79INMBINmune Bio$160K1,208.59N/AN/A$2.07 per share5.13IVCInvacare$872.46M0.00N/A0.77$5.54 per share0.00LVTXLAVA Therapeutics$6.77MN/AN/AN/A$3.39 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDFCardiff Oncology-$41.44M-$0.93N/AN/AN/A-8,492.01%-50.13%-44.31%5/2/2024 (Estimated)INMBINmune Bio-$30.01M-$1.67N/A∞N/A-19,360.00%-64.11%-45.57%5/1/2024 (Estimated)IVCInvacare-$45.56M-$2.18N/AN/AN/A-9.99%-37.76%-7.18%N/ALVTXLAVA Therapeutics-$41.97M-$1.59N/AN/AN/A-620.09%-68.54%-35.68%6/13/2024 (Estimated)Latest LVTX, IVC, TSTL, CRDF, and INMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023INMBINmune BioN/A-$0.47-$0.47-$0.47N/A$0.03 million3/20/2024Q4 2023LVTXLAVA Therapeutics$0.16-$0.24-$0.40-$0.24$25.00 million$0.35 million2/29/2024Q4 2023CRDFCardiff Oncology-$0.26-$0.21+$0.05-$0.21$0.08 million$0.16 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRDFCardiff OncologyN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/AIVCInvacareN/AN/AN/AN/AN/ALVTXLAVA TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDFCardiff OncologyN/A7.417.41INMBINmune BioN/A2.162.16IVCInvacare4.821.320.78LVTXLAVA Therapeutics0.016.626.62OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDFCardiff Oncology16.29%INMBINmune Bio12.72%IVCInvacare59.87%LVTXLAVA TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCRDFCardiff Oncology6.30%INMBINmune Bio36.10%IVCInvacare6.90%LVTXLAVA Therapeutics0.79%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCRDFCardiff Oncology3144.68 million41.86 millionOptionableINMBINmune Bio1118.20 million11.63 millionOptionableIVCInvacare3,00037.76 million35.15 millionOptionableLVTXLAVA Therapeutics37N/AN/AOptionableLVTX, IVC, TSTL, CRDF, and INMB HeadlinesSourceHeadlineBuy Rating Affirmed for LAVA Therapeutics Amid Promising T-Cell Cancer Therapy Trials and Strong Financialsmarkets.businessinsider.com - March 25 at 2:46 AMLAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Resultsfinance.yahoo.com - March 20 at 9:17 AMLAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Resultsglobenewswire.com - March 20 at 7:00 AMLAVA Therapeutics N.V.: LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)finanznachrichten.de - March 6 at 6:45 PMLava gets $7M from Pfizer as trial for cancer drug advancesmsn.com - March 5 at 10:44 AMLAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)globenewswire.com - March 5 at 7:30 AMAnalysts Are Bullish on Top Healthcare Stocks: AdaptHealth (AHCO), LAVA Therapeutics (LVTX)markets.businessinsider.com - March 1 at 9:35 AMLAVA Therapeutics Stock (NASDAQ:LVTX), Short Interest Reportbenzinga.com - February 21 at 4:27 PMLAVA Therapeutics NV (LVTX)investing.com - February 14 at 3:12 PMLava signs collaboration agreement with MSD for prostate cancer therapymsn.com - January 25 at 8:11 PMPCSA, ONCO and KAVL among mid-day moversseekingalpha.com - January 25 at 3:11 PMLAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®finance.yahoo.com - January 25 at 10:11 AMLAVA Therapeutics N.V. (LVTX)ca.finance.yahoo.com - December 13 at 8:17 AMLAVA Therapeutics NV LVTXmorningstar.com - November 11 at 10:20 AMlava lamphackaday.com - October 10 at 8:33 AMLava Therapeutics is latest life sciences company to trim its workforcebizjournals.com - August 25 at 3:39 PMLAVA Therapeutics N.V.: LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Resultsfinanznachrichten.de - August 22 at 9:28 AMLAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Resultsfinance.yahoo.com - August 22 at 9:28 AMLAVA Therapeutics (LVTX) Price Target Decreased by 44.62% to 7.34msn.com - July 6 at 8:59 PMLAVA Therapeutics N.V.: LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runwayfinanznachrichten.de - June 14 at 1:02 PMLava Therapeutics shelves hematology drug over competitive concernsmsn.com - June 14 at 1:02 PMHC Wainwright & Co. Reiterates LAVA Therapeutics (LVTX) Buy Recommendationmsn.com - June 12 at 5:49 PMJMP Securities Remains a Buy on LAVA Therapeutics (LVTX)markets.businessinsider.com - June 9 at 1:23 AMLAVA Therapeutics to Participate in the Jefferies Healthcare Conferencefinance.yahoo.com - June 1 at 10:23 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCardiff OncologyNASDAQ:CRDFCardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.INmune BioNASDAQ:INMBINmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03 develop pre-clinical data in cancer that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.InvacareNYSE:IVCInvacare Corp. engages in the manufacture and distribution of medical equipment used in non-acute care settings. It focuses on medical device solutions for congenital, acquired, and degenerative ailments. The firm operates through the following segments: North America and Europe. The company was founded by Aaron Malachi Mixon III in 1979 and is headquartered in Elyria, OH.LAVA TherapeuticsNASDAQ:LVTXLAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.